Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ISS - Eurobio Scientific: EB Development rises above 90% threshold

Company: Eurobio Scientific Date: 2025-05-19 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

![](_page_0_Picture_1.jpeg)

# **EB Development rises above 90% threshold**

**Paris, May 19, 2024 – 7:00 pm - Eurobio Scientific** (FR0013240934, ALERS, PEA-PME eligible), a leading French group in *in vitro* medical diagnostics and life sciences, was informed today by EB Development that it had exceeded the threshold of 90% of the company's share capital. This threshold crossing results from the acquisition by EB Development of Eurobio Scientific shares on the market.

EB Development now holds 9,224,652 shares, or 90.01% of Eurobio Scientific's share capital and 90.01% of its voting rights.

# **Next financial meeting**

Annual General Meeting: June 19, 2025

### **About Eurobio Scientific**

Eurobio Scientific is a major player in the field of specialty in vitro diagnostics. It is involved from research to marketing of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and offers dedicated reagents for research laboratories, including pharmaceutical and biotechnology companies. With its numerous partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary products. The Group has around 320 employees, four production units based in the Paris region, Germany, the Netherlands and the USA, and subsidiaries in Milan (Italy), Dorking (UK), Sissach (Switzerland), Bünde (Germany), Antwerp (Belgium) and Utrecht (Netherlands).

Eurobio Scientific's reference shareholders are the funds IK Partners and NextStage AM, together with its two directors Jean-Michel Carle and Denis Fortier. For further information, visit

Eurobio Scientific shares are listed on Euronext Growth Paris. Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.mnemonic: ALERS - ISIN code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

#### **Contact**

#### **Eurobio Scientific Group**

Denis Fortier, Chairman and CEO Olivier Bosc, Executive Vice-President / CFO Tel. +33 1 69 79 64 80

TEPA FCPI

## **Calyptus**

Mathieu Calleux Investor Relations Tel. +33 1 53 65 68 68 eurobio-scientific@calyptus.net

![](_page_0_Picture_16.jpeg)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now